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Abstract
Background: Skin wound healing includes a system of biological processes, collectively restoring the integrity of
the skin after injury. Healing by second intention refers to repair of large and deep wounds where the tissue edges
cannot be approximated and substantial scarring is often observed. The objective of this study was to evaluate the
effects of mesenchymal stem cells (MSCs) in second intention healing using a surgical wound model in sheep.
MSCs are known to contribute to the inflammatory, proliferative, and remodeling phases of the skin regeneration
process in rodent models, but data are lacking for large animal models. This study used three different approaches
(clinical, histopathological, and molecular analysis) to assess the putative action of allogeneic MSCs at 15 and
42 days after lesion creation.
Results: At 15 days post-lesion, the wounds treated with MSCs showed a higher degree of wound closure, a higher
percentage of re-epithelialization, proliferation, neovascularization and increased contraction in comparison to a
control group. At 42 days, the wounds treated with MSCs had more mature and denser cutaneous adnexa
compared to the control group. The MSCs-treated group showed an absence of inflammation and expression
of CD3+ and CD20+. Moreover, the mRNA expression of hair-keratine (hKER) was observed in the MSCs-
treated group 15 days after wound creation and had increased significantly by 42 days post-wound creation.
Collagen1 gene (Col1α1) expression was also greater in the MSCs-treated group compared to the control
group at both days 15 and 42.
Conclusion: Peripheral blood-derived MSCs may improve the quality of wound healing both for superficial
injuries and deep lesions. MSCs did not induce an inflammatory response and accelerated the appearance
of granulation tissue, neovascularization, structural proteins, and skin adnexa.
Keywords: Wound healing, Mesenchymal stem cells, Cell therapy, Regenerative medicine
Background
Skin is a multilayer organ that primarily functions as a
protective barrier against the external environment, pre-
venting dehydration and the penetration of external mi-
croorganisms [1]. Loss of the integrity of large portions
of the skin, as a result of injury, may result in health is-
sues, and poor quality of life [2]. Wound healing is a
complex process that begins after injury and proceeds
through three phases: hemostasis and inflammation,
proliferation, and remodeling [3–5]. These phases are
regulated by various cells, cytokines, and growth factors
regulate these phases [3–5].
Wound healing re-establishes the skin’s tensile
strength and natural barrier function [6, 7]. Dysfunc-
tional healing can lead to lifelong disability and an eco-
nomic impact on breeding [8, 9]. To optimize wound
healing, cell therapy may be an option for treating exten-
sive and chronic wounds. The presence of mesenchymal
stem cells (MSCs) in normal skin [10, 11] and their role
in natural wound healing [11, 12] indicates that the use
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of exogenous MSCs might be a means to treat wounds.
MSCs are self-renewing, expandable, and able to differ-
entiate into different cell lineages such as osteoblasts,
adipocytes, chondrocytes, tenocytes, and myocytes [13–
15]. Although bone marrow is one of the most common
sources used to obtain MSCs [16, 17], other less invasive
sources were used, such as peripheral blood, adipose tis-
sue, and skin [11, 13, 14, 18–22].
The involvement of MSCs in the wound-healing
process is significant. MSCs may regulate and improve
the three phases of wound healing [23], contribute to
the reduction of inflammation [7, 24], promote angio-
genesis, reduce excessive wound contraction, attenuate
scar formation [7, 25], and stimulate cell movement dur-
ing epithelial remodeling [8]. Moreover, the immunosup-
pressive properties of MSCs allow for their potential use
in allogeneic therapy. Although stem cell involvement in
cutaneous wound healing has been studied in rodent
models [22, 25, 26], this process has not been evaluated
extensively in large animal models.
The aim of this study was to evaluate the specific ef-
fects of allogeneic MSCs in a sheep surgical wound
model based on clinical, histopathological and molecular
analyses. Moreover, macroscopic and microscopic study
were carried out for testing the improvement of the re-
generate tissue in the presence of MSCs, in the context
of natural regeneration.
Methods
Animal model
Six female Bergamasca sheep of similar size and age,
provided by a local farm, were acclimated to a stall
(MAPS Department, University of Padua, Legnaro, Italy)
for 2 weeks. Parasitological and biochemistry examina-
tions were performed. The experiment was approved by
The Body for the Protection of Animals (OPBA), minis-
terial decree n° 51/2015-PR released by the Health De-
partment of Italy. Sheep were chosen because they are
less neurologically developed than carnivores and
equines and have sufficient superficial space on their
backs for creation of experimental lesions. Moreover,
sheep are also considered a possible research animal
model for human medicine too [27–29]. The number of
sheep was chosen based on sample size calculation and
the “3Rs” principle (replacement-reduction-refinement)
[30]. At the end of project, the animals were not sacri-
ficed but located in a teaching farm.
Isolation of peripheral blood derived MSCs (PB-MSCs)
from sheep
MSCs were isolated from the peripheral blood (PB) of six
sheep that were not part of the wound model experimen-
tal design. From each animal, 100 ml of blood was taken
from the jugular vein using a vacutainer containing the
anticoagulant Li-heparin. The mononuclear cells were iso-
lated using the protocol of Martinello et al. [13]. Briefly,
the blood was diluted 1:1 with PBS (phosphate-buffered
saline) and placed on Ficoll-paque solution (Amersham
Biosciences) to obtain mononuclear cells in interphase
after centrifugation. Cultures were maintained at 37 °C
with 5% CO2 in growth medium (DMEM 5671,
Sigma-Aldrich) with 10% FCS (fetal bovine serum,
Euroclone). On the day of application, PB-MSCs were
trypsinized with 0.25% trypsin-EDTA (Euroclone, Italy)
and resuspended in hyaluronic acid (Hyalgan®, Fidia).
Experimental design
In respect of the 3Rs principle [30], six lesions were per-
formed according to the protocol established by Broeckx
et al. [31], equidistant and symmetrical with each other on
the back of six sheep to analyze the effect of five different
therapeutic treatments (three conventional topical cream
or gel, cold ionized plasma and MSCs). The distance of
each lesion did not influence the result of trials. Six
full-thickness square wounds (4 × 4 cm) were created on
the back of six sheep. The lesions were created using a
scalpel and a square guide model under sterilize surgical
condition while the animals were under general anesthesia
with analgesia [31]. In the present study, only the
PB-MSCs treatment was evaluated and compared to phos-
phate saline buffer (PBS), used as placebo treatment.
In all six sheep, 1 × 106 PB-MSCs diluted in 1 ml of
PBS were injected in the margins of the lesion dedicated
to the MSCs study, and 1 × 106 PB-MSCs diluted in 1 ml
of hyaluronic acid were topically applied at the center of
the same lesion. In the control lesions of all six sheep,
PBS only was administered topically to the wounds.
After the application of the treatments, the lesions were
bandaged with sterile gauze using the “wet-to-dry”
method. The wounds were cleaned daily with PBS and
the bandages were changed daily.
At two different time points (15 and 42 days from the
induction of the lesions), two samples for each lesion
treated with PB-MSCs and two samples for each control
lesion were collected by means of a 6-mm punch biopsy
with appropriate sedation and analgesic drug administra-
tion. Of the two collected samples for each time point,
one was used for histopathological and immunohisto-
chemistry protocols and one for molecular analyses.
Clinical evaluation
Lesion appearance was documented daily with photo-
graphs, using a ruler to measure wound size. Every week,
the same-blinded investigator performed a clinical evalu-
ation of the study animals. The observations were catalo-
gued using the scoring system developed by Hadley et al.
[32] (Table 1). The percentages of re-epithelialization and
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wound contraction were measured at 7, 14, 21, 28 and
42 days post-wound creation.
Histopathological analysis
All 24 biopsy samples (6 PB-MSC at day 15, 6 PB-MSC
at day 42, 6 control at day 15, 6 control at day 42) were
used for histological evaluation and were glowed in
OCT (Kaltek) and frozen in isopentane and liquid nitro-
gen. Samples were cut with cryostat into 5 μm slices be-
fore being mounted on slides and stained with
Hematoxylin and Eosin (H&E). In order to obtain a full
thickness examination, all samples were examined at dif-
ference depth (six chosen points). The presence of der-
mal and subcutaneous infiltrates, (immature)
granulation tissue, undifferentiated mesenchymal tissue,
and the development of adnexa were evaluated and
scored using a 0 to 4 scale (0 absence, 1 presence, 2
small amount, 3 moderate amount, 4 abundant amount).
Data were presented as percentage of relative frequency
of the assigned values and calculated for each subject
and for each parameter.
Immunohistological evaluation
The serial slices used for histopathological analysis were
immunostained with polyclonal rabbit anti-human CD3
(Dako, 1:100), polyclonal rabbit anti-human CD20
(Thermo Fisher, 1:100), monoclonal mouse anti-human
MHCII (Dako, 1:40), monoclonal mouse anti-human
Ki67 (Dako, 1:10), and monoclonal rabbit anti-human
vWF (Dako; 1:3200) antibodies. Immunolabeling was
achieved with a high-sensitive horseradish spell out (PO)
mouse or rabbit diaminobenzidine kit, with blocking of
endogenous PO (Envision DAB+kit; Dako) in an autoim-
munostainer (Cytomation S/N S38–7410-01; Dako). An
antibody diluent (Dako), with background-reducing
components was used to block hydrophobic interactions.
The average of three fields from each slice was used to
quantitatively evaluate different immunohistological pa-
rameters and all measurements were performed with a
computer-based program (Leica microscope DM LB2
with Leica Application Suite LAS V4.0) using 20×
magnification.
Real-time PCR analysis of Col1α1 and hKER gene
expression
All 24 biopsy samples (6 PB-MSC at day 15; 6 PB-MSC at
day 42; 6 control at day 15; 6 control at day 42) were used
for molecular biology. Total RNA extraction was per-
formed using Trizol (Life Technologies) reagent and
quantified on a Nanodrop spectrophotometer (Thermo
Scientific). The complementary DNA (cDNA) was synthe-
tized to perform Real-Time PCR using the ABI 7500
Real-Time PCR system (Applied Biosystems) to evaluate
Collagen 1α1 (Col1α1) and hair keratin (hKER) gene ex-
pression. All samples were tested in triplicate and un-
treated skin was used as a calibrator sample. The 2-ΔΔct
method was used to analyze and normalize the RNA ex-
pression of the target genes with respect to endogenous
housekeeping genes.
RPS24 - forward 5’ TTTGCCAGCACCAACGTTG 3′,
reverse 5’AAGGAACGCAAGAACAGAATGAA 3′,
18S - forward 5’AAACGGCTACCACATCCAAG 3′,
reverse 5’ TCCTGTATTGTTATTTTTCGTCAC 3′.
PCR primers were designed using Primer Express 3.0
software (Applied Biosystems). The sequences for the
forward and reverse primers specific for each mRNA
were as follows:
COL1α1 – forward 5’ GTACCATGACCGAGACGTGT 3′,
reverse 5’AGATCACGTCATCGCACAGCA 3′;
hKER – forward 5’ TGGTTCTGTGAGGGCTCCTT 3′,
reverse 5’ GGCGCACCTTCTCCAGGTA 3′.
Statistical analysis
Data on clinical, histological, molecular, and immunohis-
tochemical parameters were analysed using PROC
MIXED, with animal as a random effect and repeated
Table 1 Skin-healing parameters scored in the experiment
Parameter Score
Presence of exudate 1 absent
2 small
3 moderate
4 abundant
Color of exudate 1 clear
2 pink/red
3 brown
4 yellow
5 green
Character of exudate 1 serous
2 serosanguineous
3 sanguineous
4 purulent +
5 purulent ++
6 purulent +++
Gauze 1 dry/clean
2 dry/stained
3 moist
4 wet
Hydration 1 Normal
2 Maceration +
3 Maceration ++
4 Desiccation +
5 Desiccation ++
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effect. The statistical linear model included the fixed ef-
fect of treatment (MSCs vs Placebo), time (week1, 2, 3,
4, 5, 6) and their interaction. The assumptions of the lin-
ear model were graphically inspected using residuals
plots. For data that were not normally distributed (Sha-
piro-Wilks test < 0.90), the Mann-Whitney test was used
(wound closure time, % of re-epithelialization and con-
traction, presence of exudate). The level of statistical sig-
nificance was set at p < 0.05.
Results
Assessment of the healing process
Wound closure time for the PB-MSCs treated wounds
was slightly quicker than that of the control group,
average of wound closure time of six sheep was re-
spectively 30.05 and 31.80 days (Fig. 1a-b). However,
this was not a significant difference. Two weeks after
wound creation, all animals in both the
PB-MSCs-treated group and the control group had
less than 40% re-epithelialization. Between day 14 and
28, the PB-MSCs-treated lesions had a higher percent-
age of re-epithelialization in comparison with the con-
trol group (58.69% vs 49.89% at day 21 and 93.5% vs
87% at day 28). However, this was not a significant dif-
ference. After 42 days of treatment, all wounds had
100% re-epithelialization(Fig. 2a). After two weeks of
treatment, the PB-MSCs-treated wounds showed 81%
contraction compared to 78% for the control PBS
group. However, this was not a significant difference.
All lesions had 100% contraction after 42 days of treat-
ment (Fig. 2b).
Evaluation of skin-healing parameters
The PB-MSCs-treated wounds had a slight, but
not-significant increase, in exudate compared to the
control group. By the second week, exudate was absent
from all lesions in both groups. For all lesions, the color
of the exudate was pink/red and changed from serosan-
guinous to sanguineous over the course of the study.
During the first week post-wound creation, the gauze
from all PB-MSCs-treated wounds was dry and clean
while those of the PBS control group were slightly moist.
However, this was not a significant difference. The
wounds, from both groups, showed a normal state of
hydration.
Histopathological examination
Dermal inflammation: at day 15, 33% of PB-MSCs-treated
wounds presented with a moderate amount of dermal in-
flammation, while 67% presented with a small amount. In
comparison, after 15 days, 50% of the control group pre-
sented with a moderate amount of dermal inflammation
and 50% presented with a small amount. After 42 days, in-
flammation was completely absent in the PB-MSCs
treated group, while 60% of the control group presented
with a small amount of inflammation.
Subcutaneous inflammation: at day 15, 83% of
PB-MSCs-treated wounds contained a small amount of
subcutaneous inflammation. In contrast, 17% of the con-
trol group presented with moderate and 67% presented
with a small amount of inflammation. After 42 days,
subcutaneous inflammation was absent in all samples.
Immature granulation tissue: at day 15, all of the
wounds in both groups presented an abundant amount
Fig. 1 Macroscopic analysis and the percentage of days of healing. a Serial macroscopic images of the wound site at different time points after
PB-MSCs and PBS treatment. Between day 21 and 28, a smaller wound diameter and higher wound closure rate was observed in PB-MSCs-treated
wounds. b The panel represents the percentage of days of healing. The wound closure time of the PB-MSC treated wounds (30,05 days) was
slightly faster respect than the PBS-treated group (31,80 days)
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of immature granulation tissue (Fig. 3). Granulation tis-
sue was absent from all wounds by day 42.
Undifferentiated mesenchymal tissue and cutaneous ad-
nexa: undifferentiated mesenchymal tissue and cutaneous
adnexa were observed only in samples collected at day 42.
Hair follicles, sebaceous, and apocrine glands were present
in all samples but the cutaneous adnexa observed in
PB-MSCs-treated wounds appeared more mature and
denser compare to the control group (Fig. 3).
After 15 days of treatment, ulceration was still present
in all the samples. Complete re-epithelization was de-
tected at day 42 in all samples.
Quantitative analysis of inflammatory, proliferative,
vascular and structural factors
Quantitative immunohistochemical staining showed any
increase of CD3+ and DC20+ positive cells was similar in
both groups. A higher number of MHCII+ cells (p < 0.5)
was observed after 15 days in PB-MSCs treated wounds
(0.45 ± 0,03) compared to control group wounds (0.25 ±
0.02); this was not the case at day 42.
Within the newly formed dermis, the lesions treated
with PB-MSCs had a higher Ki67 expression (0,661
± 0,05) compared to the control group (0.313 ± 0,03).
After 42 days, Ki67 expression, in both groups, began to
Fig. 2 Re-epithelialization and skin contraction. a The percentage of re-epithelization. b Percentage of contraction after 7, 14, 21, 28 and 42 days
of treatment. PB-MSCs-treated wounds trend is represented by black lane, while PBS control group is indicated in grey lane
Fig. 3 Representative photomicrographs of PBS and PB-MSCs treated wounds (Hematoxylin-Eosin). Photomicrographs of PBS and PB-MSCs
treated wounds analyzed at 15 and 42 days from treatments. The images show the presence of immature granulation tissue at 15 days, while
mature connective tissue and developing cutaneous adnexa are present at 42 days. The lack of epidermis in representative image of PB-MSCs
treated wounds at 42 days is an artefact. Scale bar 151,7 μm
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decrease (Fig. 4). Using von Willebrand Factor (vWF)
antibody staining, more dermal neovascularization was
noticed in the PB-MSCs-treated wounds (4.15 ± 0,07)
compared with the control lesions (3.32 ± 0,08) (p < 0.5).
Neovascularization decreased in both groups during the
wound healing process, showing the same protein ex-
pression values after day 42 (Fig. 4).
The molecular analysis (RT-PCR) of the Col1α1 gene
indicated that at day 15 and 42, mRNA expression levels
were statistically significant (p < 0.5) in the wounds
treated with PB-MSCs (day 15: 75.09 ± 6,5, day 42: 87.65
± 7,1) compared to the control group (day 15: 47.40 ±
3,6, day 42: 45.80 ± 5,3). PBS treatment did not influence
the mRNA expression level of the Col1α1 gene (Fig. 5).
After 15 days, hKER mRNA expression (0.552 ± 0,05)
was already present in the wounds treated with
PB-MSCs. Furthermore, at day 42, the hKER expression
level (5.016 ± 0,1) significantly (p < 0.5) increased in the
PB-MSCs-treated lesions, but not in the control group’s
lesions. Control PBS alone did not stimulate cutaneous
adnexa formation after 15 and 42 days (Fig. 5).
Discussion
MSCs represent a promising solution to promoting
wound healing. The presence of these cells in normal
skin [10] suggests their important role in maintaining
skin homeostasis. There are different types of stem cells
in the epidermis, dermis, and hair follicles [33], which
preserve the cellular state of the tissues. Several in vivo
studies performed in small laboratory animals have dem-
onstrated that stem cells accelerate wound healing.
Many studies have hypothesizing that stem cells contrib-
ute to re-epithelization, vascularization, and extracellular
remodeling [34–36]. The present study investigated the
influence of allogeneic PB-MSCs treatment in a large
animal experimental second intention wound healing
model, evaluating their short and long-term effects on
skin regeneration. Healing associated with a large and/or
deep wound in which the tissue edges cannot be approx-
imated is called secondary intention [37]. Wounds are
left open to heal with the production of granulation tis-
sue, followed by contraction and epithelialization [38].
Often, this type of healing can be associated with sub-
stantial scarring [37]. A previous study, using a murine
model, showed that stem cells seeded on a nanostruc-
tured membrane helped primary intention healing, such
as found with dermal burns [39]. Since MSCs are active
in different phases of the healing process, it was hypoth-
esized that they may also be used as a treatment for lar-
ger wounds that heal by second intention.
After skin injury, the inflammatory phase starts imme-
diately. During this process, platelets aggregate at the in-
jury site followed by the infiltration of neutrophils,
macrophages, and T-lymphocytes [3]. The data pre-
sented in this paper show that there was no significant
difference in level of inflammation between PBS-treated
Fig. 4 Immunohistochemistry analysis. Percentage of positive staining for CD3, CD20, MHCII, KI67, vWF in PB-MSCs-treated wounds (black bars)
and PBS control group (grey bars). Each graph represents the main ± SD of wound treated with PB-MSCs and saline solution PBS. Asterisk
indicates significant differences between PB-MSCs group and PBS control group (p < 0.05)
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and PB-MSCs-treated wounds. Microscopic evaluation
indicated the presence of the inflammation phase 15 days
post-injury in both the PBS control group and the
PB-MSCs group at the dermal and subcutaneous levels.
A notable result from the study was the complete ab-
sence of inflammation after 42 days in the PB-MSCs
group whereas 60% of the PBS control group still pre-
sented with dermal inflammation. These results corrob-
orate the findings of other studies. For example, Kim et
al. [40] showed that experimental full-thickness wounds
treated with topical allogeneic MSCs had increased heal-
ing and less inflammation, possibly due to the release of
immunosuppressive factors in the wound bed that in-
hibit proliferation of immune cells such as B cells, T
cells, and natural killers cells [41, 42]. This effect of allo-
genic MSCs was shown, in the current study, by absence
of an increase of CD3+ and CD20+ cells (B lympho-
cytes) in MSCs-treated wounds. As discussed by Hussein
et al. [43], CD3+ co-receptors helps to activate cytotoxic
T lymphocytes, which constitute most of the mono-
nuclear inflammatory cell infiltrate. Moreover, in the last
decade, it has been found that MSCs also possess an
antimicrobial effect, which helps to reduce excess in-
flammation from wound contaminants [44] and in the
scar formation process [45]. The anti-inflammatory ef-
fect of PB-MSCs observed in the current study may re-
sult in a shortened inflammatory phase, thereby
reducing myofibroblast and fibrocyte development and
scar formation [46, 47].
After the inflammation phase, there is the proliferative
phase with newly formed granulation tissue that covers
the wound area to complete tissue repair. This phase is
characterized by angiogenesis, which is important for
attracting cytokines, sustaining the granulation tissue,
and re-epithelization [48]. Histologically, the granulation
tissue, evaluated in this study, was more abundant in
wounds treated with PB-MSCs, although the amount of
granulation tissue decreased for both cases and controls
over time. The newly formed granulation tissue was seen
at 15 days post-wound creation both in PBS and
PB-MSCs-treated wounds. Evidence of proliferative ac-
tion by PB-MSCs was confirmed by an increase in Ki67
expression, with this protein present during all active
phases of the cell cycle. The PB-MSCs treatment pro-
duced a significant increase in Ki67 expression com-
pared to PBS treatment alone, which correlated with the
presence of more abundant granulation tissue.
The increase in matrix and vessel formation, after
MSCs treatment, may be attributed to the observed
up-regulation of growth factors such as EGF, TGF-β1,
and stromal-derived growth factor-1α [49]. The more ac-
tive proliferation induced by PB-MSCs treatment was
reflected by an increase in the percentage of
re-epithelialization and contraction observed clinically.
At 28 days, 93,5% of PB-MSCs-treated wounds were
re-epithelized versus 87% of PBS treated wounds. In
addition, wound contraction appeared earlier in the
PB-MSCs-treated group. The histological data, obtained
in this study, confirmed that MSCs might produce mul-
tiple pro-angiogenic factors at the lesion site, which
stimulate endothelial cells and lead to new blood vessel
formation in the wound bed. Revascularization of the
wound bed is an important part of the normal wound
healing process. Formation of new vessels is necessary to
carry blood to the wound area, which requires oxygen
and nutrients [50, 51].
The last phase of wound healing is maturation of the tis-
sue. Collagen type 1 is the predominant collagen in nor-
mal skin and exceeds collagen type 3 by a ratio of 4:1.
During wound healing, this ratio decreases to 2:1 because
of an early increase in the deposition of collagen type 3. In
this study, the expression of matrix protein collagen 1 was
higher in PB-MSCs-treated wounds compared to only
treatment with PBS at both 14 and 42 days, indicating an
earlier process of wound healing. Moreover, in normal
skin, a population of multipotent stem cells capable of
generating all of the components of hair, as well as epithe-
lial cells, is located in the hair follicle bulge [52]. These
cells do not contribute to preservation of the interfollicu-
lar epidermis, but can differentiate into epidermal stem
Fig. 5 Analyses of mRNA gene expression. mRNA expression of Col1α1 and hKER in PB-MSCs-treated wounds (black bars) and PBS control group
(grey bars). Col1α1 and hKER were highly expressed in the treated wounds. Asterisk indicates significant differences between PB-MSCs and PBS
control groups (p < 0.05)
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cells after a trauma [53]. In the current study, the treat-
ment of wounds with allogeneic PB-MSCs resulted in the
development of new hair follicles and probably also the
activation of bulge cells.
Overall, the findings of this large animal study were
similar to results from small animal studies. In fact, le-
sions created in rabbits and dogs [54, 55] demonstrated
significantly earlier vascularization, fibroplasia, and mat-
uration of collagen using autologous bone
marrow-derived mononuclear cells compared to a con-
trol group. Formigli L et al. [56] demonstrated that
MSCs seeded on bioengineering scaffolds induced en-
hanced re-epithelialization characterized by a multi-
layered epidermis, return of hair follicles, sebaceous
glands, and enhanced blood vessel formation. The
current study showed that treatment with PB-MSCs
leads to a significant increase in the expression of hair
keratin mRNA, with expression detectable at 14 days
post-wound creation. Furthermore, after 42 days, micro-
scopic evaluation showed an increased in hair follicles,
sebaceous and apocrine glands in the PB-MSCs-treated
group compared to the control group.
Conclusion
In the skin regeneration process, PB-MSCs play roles in
different phases of wound healing, contributing to the
healing process and, as it is confirmed from our paper,
does not induce an inflammatory response. Despite
some analyzed parameters did not show significant re-
sults the trend suggests a beneficial use of PB-MSCs not
only for treating superficial injuries, but also for deeper
lesions. PB-MSCs were able to speed up the appearance
of granulation tissue, stimulate neovascularization, and
increase structural proteins and skin adnexa.
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